Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,409 across all filing types
Latest filing 2015-03-09 Investor Presentation
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
CP NCIC
Investor Presentation Classification · 95% confidence The document is dated March 9, 2015, and announces that investigators presented the rationale and protocol for a Phase I/II clinical trial (IND.221) involving IPH2201 for ovarian cancer at the 'Targeted Anticancer Therapies' (TAT) congress. The text explicitly states that the presentation occurred at a congress and that the presentation itself is available on the company website. This structure—announcing an event where data/protocol was presented, rather than being the full clinical study report or a mandatory regulatory filing like a 10-K or IR—strongly suggests it is a press release or an announcement about investor/scientific communication. Since it details scientific progress, clinical trial updates, and partnership news, it functions as an Investor Presentation (IP) or a general press release. Given the content focuses heavily on the scientific rationale, trial design, and future plans presented at a conference, 'Investor Presentation' (IP) is the most fitting category, as these press releases often summarize or announce the content of such presentations. It is not a formal regulatory filing (10-K, AR, IR) nor a simple dividend/share change notice. It is an announcement of scientific/clinical progress.
2015-03-09 French
PR NCIC
Investor Presentation Classification · 92% confidence The document is a press release dated March 9, 2015, announcing a collaboration between Innate Pharma and NCIC Clinical Trials Group regarding a Phase I/II trial for IPH2201 in ovarian cancer. It details scientific rationale, trial structure, and background information on the drug and the disease. This type of announcement, focusing on clinical trial progress, scientific updates, and partnership news, is typically classified as an Investor Presentation (IP) if it were a deck, or often falls under general Regulatory Filings (RNS) or sometimes an Earnings Release (ER) if it contained key financial metrics. However, since it is a detailed announcement about clinical development and scientific findings, and not a formal financial report (like 10-K or IR) or a transcript (CT), the most appropriate category for a detailed, non-financial-results-focused corporate update that disseminates strategic/pipeline information to investors is Investor Presentation (IP), even though it is in press release format, as it serves the function of presenting pipeline data. Given the options, and the focus on clinical trial protocol presentation at a congress, IP is the best fit for conveying strategic pipeline information to investors.
2015-03-09 English
Annual report 2014 IPH
Earnings Release Classification · 94% confidence The document is titled "ANNUAL RESULTS 2014" and explicitly states that the company "reports today its consolidated financial results for the year ended December 31, 2014." It contains detailed IFRS consolidated financial statements (Income Statement, Balance Sheet) for the full year, which is characteristic of an Annual Report or a comprehensive year-end financial disclosure. Although it mentions the full financial statements are 'attached to this press release' and that the 'financial annual report, included in the reference document, will be available in the second quarter of 2015,' the core content provided is the detailed annual financial summary and management discussion, which strongly aligns with the scope of a 10-K (Annual Report) or a very detailed Earnings Release/Interim Report. Given the comprehensive nature, the inclusion of full comparative financial tables for the entire year ended December 31, 2014, and the reference to the 'annual report' being filed later, this document functions as the primary release of the annual financial performance data. However, since it is a press release announcing the results and explicitly states the full statements are attached/will be filed later, it could be argued as an Earnings Release (ER) or a Report Publication Announcement (RPA). Since the document contains the actual detailed financial tables and management commentary for the full year, it goes beyond a typical ER (which is usually just highlights) and is more comprehensive than an RPA. In many jurisdictions, this detailed press release serves as the initial public release of the 10-K data. Given the depth of the financial tables and the focus on the full fiscal year results, it is closest to the content of an Annual Report (10-K), but because it is framed as a press release announcing the results and referencing the final filing, classifying it as an Earnings Release (ER) or a comprehensive Interim Report (IR) might be more accurate if 10-K is reserved strictly for the SEC filing itself. Since it covers the full year and includes detailed financials, it is the precursor to the 10-K. Given the options, and the fact that it is a comprehensive annual financial summary, it is best classified as an Earnings Release (ER) as it is the initial announcement of the annual results, even though it is very detailed. If the document were significantly shorter and only pointed to the attached report, RPA would be chosen. Since it contains the core data, ER is the best fit among the release types, though it has 10-K characteristics. FY 2014
2015-02-19 English
rapport annuel 2014 IPH
Earnings Release Classification · 95% confidence The document is titled with 'RÉSULTATS 2014' (2014 Results) and contains a detailed summary of financial highlights, including a consolidated income statement table for the fiscal year 2014 compared to 2013, and mentions that the consolidated financial statements are attached. It also discusses clinical pipeline advancements and corporate news for the year 2014. The text explicitly states that the annual consolidated financial statements are presented and that the full annual financial report will be available later. The presence of detailed financial tables covering a full fiscal year (2014) strongly suggests this is an Annual Report or a document closely related to it. However, the structure—a press release announcing the results, mentioning that the full statements are attached, and noting the formal annual report will follow—is characteristic of an Earnings Release (ER) or a comprehensive Interim/Quarterly Report (IR) if it were for a shorter period. Since it covers the full year (2014 results) and includes detailed financial tables, it functions as the primary release of annual financial performance. Given the options, 'ER' (Earnings Release) is the closest fit for the initial announcement of annual results, even though it contains more detail than a typical quarterly ER. If the document were the full, audited 10-K, it would likely be titled as such or be much longer and filed with a regulator like the SEC (this appears to be a French company filing). Since it is a comprehensive announcement of the full year's results, 'ER' is the most appropriate classification among the choices provided for an initial results announcement, although it borders on being a full Annual Report (10-K) substitute for a non-US filer, or an 'IR' if it were a half-year report. Given the context of 'Résultats annuels' and the detailed financial breakdown, it is the primary release of annual performance data, fitting the 'ER' definition best as the initial announcement of periodical financial results. FY 2014
2015-02-19 French
CP Nombre d'actions
Share Issue/Capital Change Classification · 98% confidence The document is titled "NOUVEAU NOMBRE D'ACTIONS ET DE DROITS DE VOTE D'INNATE PHARMA AU 31 DECEMBRE 2014" (New number of shares and voting rights as of December 31, 2014). It explicitly states it is publishing the number of shares composing the capital and the associated voting rights, referencing French commercial code and AMF (Autorité des marchés financiers) regulations. This content directly relates to changes in the company's share structure and voting rights calculation, which aligns best with the 'Share Issue/Capital Change' (SHA) definition, as it reports the final count of shares outstanding at a specific date. Although it mentions voting rights, the core data is the total share count, making SHA more appropriate than DVA (which is for voting *results*). It is not a general regulatory filing (RNS) because it fits a specific category.
2015-01-08 French
CP Bilan annuel du contrat de liquidité
Capital/Financing Update Classification · 99% confidence The document is titled "BILAN ANNUEL DU CONTRAT DE LIQUIDITE" (Annual Balance of the Liquidity Contract) dated January 8, 2015, reporting figures as of December 31, 2014. It details the status of a liquidity contract managed by Gilbert Dupont, including the number of shares and cash balance. This type of regular disclosure regarding market making or liquidity provision is often categorized as a specific regulatory filing or a general corporate announcement. Since it is a formal report on a specific financial arrangement (liquidity contract balance) and not a comprehensive annual report (10-K), earnings release (ER), or interim report (IR), it fits best under a specific category related to capital structure or a general regulatory filing. Given the options, it is a specific disclosure related to the company's market presence and capital management. It is not a dividend notice, director dealing, or management change. It is a formal report on a financial arrangement. While it could potentially fall under 'Regulatory Filings' (RNS), the content specifically relates to capital/financing activities (maintaining market liquidity). However, the most precise fit among the provided options for a formal, periodic report on a specific financial arrangement that isn't a core financial statement (10-K, IR) or an earnings release (ER) is often the general 'Regulatory Filings' (RNS) if a more specific code like 'CAP' (Capital/Financing Update) is too broad for a routine liquidity report. Since this is a formal, periodic report on a specific financial arrangement (liquidity contract), and it is not a standard financial statement, it is classified as a general regulatory filing (RNS) as it doesn't match the other specific codes well, although it touches upon capital maintenance. Given the nature of liquidity contract reporting, which is often mandated by exchange rules, RNS is the most appropriate fallback for a specific, non-standard disclosure.
2015-01-08 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.